An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
Patients are asked to participate in this study if they have been diagnosed with a thoracic carcinoma which includes lung cancer and have a gene mutation (alteration in the body's genetic instructions) and after undergoing treatment the cancer has come back, progressed, or shown a partial response on standard treatment.
Checked against the public recordLast updated Oct 19, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Mayo Clinic
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * 18 years or older * Thoracic carcinoma tumors are positive for any targetable genetic alterations * Have shown partial or no response, progression or recurrence while on or after gene targeted therapy by CT/PET scan * Tumor is accessible for biopsy or surgery * Expected life is 6 months or longer. Exclusion Criteria: * \< 18 years * Not able to communicate in English
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Mayo Clinic in RochesterRochester, Minnesota
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 19, 2020. Always confirm current availability with the study team.